Monday, October 26, 2026

How We Source Explore Search

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· May 24, 2026

Is Dell (DELL) Quietly Recasting Its AI Moat With PowerStore Elite And AI Factory Expansions?

View original at finance.yahoo.com

Is Dell (DELL) Quietly Recasting Its AI Moat With PowerStore Elite And AI Factory Expansions?…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Dell Technologies projects $9.1 billion in earnings by 2029, a $3.2 billion increase from current $5.9 billion
60% confidence
To own Dell today, investors must believe its AI infrastructure push can matter more than the cyclical PC and legacy hardware drag
60% confidence
Dell's AI servers are margin dilutive and the stock trades above average industry multiples
60% confidence
Key risks for Dell include commoditization, dependence on PC refresh cycles, and recent insider selling into a sharply higher share price
60% confidence
Analyst fair value for Dell Technologies is $168.61, implying 43% downside to its current share price
60% confidence
Dell's DriveNets Fabric Scheduled Ethernet integration targets high-performance AI clusters at scale by tying PowerEdge and PowerStore Elite hardware into denser multi-tenant GPU environments
60% confidence
Dell Technologies projects $157.5 billion in revenue by 2029, requiring 11.5% yearly revenue growth
60% confidence

Data points we hold from this source

Dell Technologies · net income

5.9 USD

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings

Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

Ford Motor Company

Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,994

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,994 facts checked against source5,500 source documents archived

Query this data → isubstrate.com